Os Therapies Incorporated shares rise 1.14% intraday after Lantern Pharma's subsidiary cleared IND application for GBM trial.

Os Therapies Incorporated rose 1.14% in intraday trading, with recent news events including Lantern Pharma's subsidiary, Starlight Therapeutics, receiving FDA clearance for a Phase Ib/2a clinical trial to evaluate STAR-001 in combination with spironolactone for patients with glioblastoma multiforme (GBM) at first progression. Additionally, Cytokinetics reported progress in regulatory reviews of Aficamten for obstructive HCM, with a late-cycle meeting with the U.S. FDA scheduled for September ahead of the December 26, 2025 PDUFA date. Genmab also reported positive developments, including the advancement of epcoritamab to earlier lines of therapy and encouraging antitumor activity in endometrial cancer for Rinatabart sesutecan.